A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

被引：56

作者：

Takahashi, R ^{[1
]}

Shimazaki, C ^{[1
]}

Inaba, T ^{[1
]}

Okano, A ^{[1
]}

Hatsuse, M ^{[1
]}

Okamoto, A ^{[1
]}

Hirai, H ^{[1
]}

Ashihara, E ^{[1
]}

Nakagawa, M ^{[1
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Med 2, Kamigyo Ku, Kyoto 6028566, Japan

来源：

LEUKEMIA RESEARCH | 2001年 / 25卷 / 01期

基金：

日本学术振兴会;

关键词：

bisphosphonate; YM529; myeloma; apoptosis;

D O I：

10.1016/S0145-2126(00)00087-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We examined the effect of YM529, a newly developed third-generation bisphosphonate (BP), on the growth of human myeloma cell lines using the trypan blue dye exclusion test and Alamar blue assay. BPs induced inhibition of proliferation in all cell lines dose-dependently, and YM529 had a most potent growth inhibitory effect, followed by incadronate and pamidronate. Flow cytometric analysis using annexinV and 7AAD showed that YM529 most significantly induced apoptosis of all myeloma cell lines. These observations suggested that YM529 is a potent apoptosis inducer of myeloma cells, and might have some benefit not only on the improvement of bone lesions but also on survival in some myeloma patients. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：77 / 83

页数：7

共 32 条

[1] A NEW RAPID AND SIMPLE NONRADIOACTIVE ASSAY TO MONITOR AND DETERMINE THE PROLIFERATION OF LYMPHOCYTES - AN ALTERNATIVE TO [H-3] THYMIDINE INCORPORATION ASSAY [J].

AHMED, SA ;

GOGAL, RM ;

WALSH, JE .

JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 170 (02) :211-224

[2] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J].

Aparicio, A ;

Gardner, A ;

Tu, Y ;

Savage, A ;

Berenson, J ;

Lichtenstein, A .

LEUKEMIA, 1998, 12 (02) :220-229

[3]

BARLOGIE B, 1989, BLOOD, V73, P865

[4] EXCESSIVE BONE-RESORPTION IN HUMAN PLASMACYTOMAS - DIRECT INDUCTION BY TUMOR-CELLS IN-VIVO [J].

BATAILLE, R ;

CHAPPARD, D ;

BASLE, M .

BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :721-724

[5] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, MJ ;

Blacklock, HA ;

Bell, R ;

Simeone, J ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493

[6] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, M ;

Blacklock, H ;

Bell, R ;

Simeone, JF ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602

[7]

Berenson JR, 1997, CANCER, V80, P1661

[8] Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease [J].

Dallas, SL ;

Garrett, IR ;

Oyajobi, BO ;

Dallas, MR ;

Boyce, BF ;

Bauss, F ;

Radl, J ;

Mundy, GR .

BLOOD, 1999, 93 (05) :1697-1706

[9] Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment [J].

Derenne, S ;

Amiot, M ;

Barillé, S ;

Collette, M ;

Robillard, N ;

Berthaud, P ;

Harousseau, JL ;

Bataille, R .

JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2048-2056

[10] Anti-myeloma activity of pamidronate in vivo [J].

Dhodapkar, MV ;

Singh, J ;

Mehta, J ;

Fassas, A ;

Desikan, KR ;

Perlman, M ;

Munshi, NC ;

Barlogie, B .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) :530-532

← 1 2 3 4 →